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Abstract
Background: A handful of studies have exploited antitumor potential of esculetin, a dihydroxy coumarine
derivative; the targets to which it binds and the possible downstream mechanism for its cytotoxicity in cancer cells
remain to be elucidated. Using pancreatic cancer cell lines as a model system, herein the study was initiated to
check the efficacy of esculetin in inhibiting growth of these cancer cells, to decipher mechanism of its action and
to predict its direct binding target protein.
Methods: The cytotoxicity of esculetin was determined in PANC-1, MIA PaCa-2 and AsPC-1 cell lines; followed by
an inspection of intracellular levels of ROS and its associated transcription factor, p65-NF-κB. The interaction
between transcription factor, Nrf2 and its regulator KEAP1 was studied in the presence and absence of esculetin.
The effect of Nrf2 on gene expression of antioxidant response element pathway was monitored by real time PCR.
Thereafter, potential binding target of esculetin was predicted through molecular docking and then confirmed in
vitro.
Results: Esculetin treatment in all three pancreatic cancer cell lines resulted in significant growth inhibition with
G1-phase cell cycle arrest and induction of mitochondrial dependent apoptosis through activation of caspases 3, 8
and 9. A notable decrease was observed in intracellular ROS and protein levels of p65-NF-κB in PANC-1 cells on
esculetin treatment. Antioxidant response regulator Nrf2 has been reportedly involved in crosstalk with NF-κB.
Interaction between Nrf2 and KEAP1 was found to be lost upon esculetin treatment in PANC-1 and MIA Paca-2
cells. Nuclear accumulation of Nrf2 and an upregulation of expression of Nrf2 regulated gene NQO1, observed on
esculetin treatment in PANC-1 further supported the activation of Nrf2. To account for the loss of Nrf2-KEAP1
interaction on esculetin treatment, direct binding potential between esculetin and KEAP1 was depicted in silico
using molecular docking studies. Pull down assay using esculetin conjugated sepharose beads confirmed the
binding between esculetin and KEAP1.
Conclusions: We propose that esculetin binds to KEAP1 and inhibits its interaction with Nrf2 in pancreatic cancer
cells. This thereby promotes nuclear accumulation of Nrf2 in PANC-1 cells that induces antiproliferative and
apoptotic response possibly by attenuating NF-κB.
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Background
Naturally occurring compounds have provided numer-
ous health benefits to human race since time immemor-
ial. A plethora of compounds have been under rigorous
screening for anticancer potential and developed as
chemotherapeutic agents [1, 2]. Amongst the coumarins,
6,7-dihydroxy derivative, commonly called esculetin, was
reported to induce antiproliferative response in several
cancer cell lines [3]. It is found in various medicinal
plants such as Cichorium intybus (Asteracea), Artemisia
capillaries (Compositae), Ceratostigma willmottianum
(Plumbaginaceae), Citrus limonia (Rutaceae) etc [4, 5].
Several reports have presented induction of apoptosis
and cell cycle arrest in human cancer cells on treatment
with esculetin [6–14]. Although these studies present an
insight into various signaling pathways that get misregu-
lated on esculetin treatment, the direct target(s) of the
compound remains to be elucidated. Further, esculetin is
a well established antioxidant [15], and thus antioxidant
responsive pathway merits attention.
Nuclear Factor-Erythroid 2-related factor 2 (Nrf2),
encoded by Nuclear Factor-Erythroid 2-like2 (NFE2L2)
gene is a major regulator of antioxidant response in cell
[16]. It is a basic region-leucine zipper (bZIP) protein
belonging to Cap ‘n’ Collar (CNC) family of transcription
factors and binds to Antioxidant Response Element (ARE)
present in promoter of a battery of genes coding for
antioxidant proteins [17]. Nrf2 signaling remains under
tight regulation by an actin binding protein, Kelch-like
ECH-associated protein1 (KEAP1) [18]. Under normal
conditions KEAP1 sequesters Nrf2 in cytoplasm and pro-
motes its ubiquitination and proteosomal degradation [19].
Owing to a number of cysteine residues present throughout
the KEAP1 protein, specifically Cys151, Cys273 and
Cys288, it senses oxidative stress and thereby liberates
Nrf2, which then gets accumulated in nucleus and activates
transcription of genes under the ARE regulation [20].
Role of Reactive Oxygen Species (ROS) in cancer
progression and treatment has always remained debat-
able. Over the past several years, it has been established
that cancer cells have far greater ROS levels than normal
cells and that ROS mediated regulation of transcription
factors like nuclear factor kappa-light-chain-enhancer of
activated B cells (NF-κB) etc are required for tumorigen-
esis, cancer cell survival, proliferation and metastasis
[21]. Considerable attention has therefore been given to
developing ROS depleting strategies to vanquish tumor
growth. Recently, activation of Nrf2 mediated ARE
signaling has emerged as an attractive strategy for treat-
ment of cancer [22, 23]. Consequently, small molecules
that inhibit Nrf2-KEAP1 interaction are springing up as
promising chemotherapeutic agents for cancer.
Using pancreatic cancer cells (PANC-1; MIA PaCa-2
and AsPC-1) as a model system, herein we first tried to
look into the potential of esculetin as an antiproliferative
and apoptotic agent. To elucidate the mechanism of
action of esculetin, cellular ROS status and level of NF-
κB was examined in PANC-1 cells on esculetin treat-
ment. Thereafter we investigated if the effect is mediated
through disruption of Nrf2-KEAP1 interaction. Finally,
we deciphered the molecular target to which esculetin
possibly binds by examining its binding potential with
KEAP1 through computer based molecular docking and
subsequently validated this interaction in vitro. We have
also examined pharmacokinetics of esculetin by using in
silico tools.
Methods
Compound
Esculetin (6,7-dihydroxycoumarin, 98 % purity) was
purchased from Sigma-Aldrich (USA) and dissolved in
dimethyl sulfoxide (DMSO, vehicle).
Cell culture
Human embryonic kidney cells – HEK 293 and Human
pancreatic carcinoma cells- PANC-1, MIA PaCa-2 and
AsPC-1 were cultured in high glucose Dulbecco minimal
essential medium (DMEM) (Sigma-Aldrich, USA)
supplemented with 10 % fetal bovine serum (GIBCO,
USA) and penicillin (60 IU/ml) / streptomycin (50 μg/ml)
at 37 °C in 5 % CO2 humidified atmosphere. The HEK
293 cell line was provided as a kind gift by Prof Vani
Brahmachari and all the three pancreatic cell lines were a
kind gift from Dr Madhu Chopra, Dr. B.R Ambedkar
Centre for Biomedical Research, University of Delhi.
Cell viability
The cells were grown up to 70 % confluency in 96 well
plates and treated with different concentration of
esculetin for the indicated time. Control cells were
supplemented with complete media containing 0.1 %
DMSO (vehicle control) for various time points. MTT
solution [0.5 % (v/v)] was prepared in Phosphate Buffer
Saline (PBS) and 20 μl of the solution was added to each
well. After incubation at 37 °C for 4 h, DMSO was added
to each well to dissolve formazan crystals. Absorbance of
each well was measured at 570 nm in ELISA plate reader
(Tecan, Gr dlg, Austria) and percentage of cell viability
was calculated with respect to vehicle control (VC).
Cell cycle analysis
The cells at 60 % confluency in T-25 flasks were
deprived of serum for 24 h. The G0 phase synchronous
population of cells thus obtained was treated with
100 μM of esculetin for different time points. After the
desired time interval, cells were washed with cold PBS,
centrifuged and fixed in 70 % (v/v) ethanol at 4 °C.
Ethanol was then removed by washing the cells twice
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with cold PBS. Cells were then incubated in PBS contain-
ing RNaseA (0.005 mg/ml) at 37 °C for 30 min.
Subsequently, Propidium Iodide (PI) (0.1 mg/ml) was
added to the cells and incubated at room temperature for
15 min in dark. The cells were then analysed for their dis-
tribution in different phases of cell cycle on FACScalibur
using CellQuestPro software (Becton Dickinson, USA).
Detection of apoptosis by Annexin-V and Propidium Iod-
ide (PI) staining
Annexin V, an apoptotic marker binds to phosphatidyl-
serine (PS) that translocates from the inner membrane
of the plasma membrane to the outer membrane during
apoptosis and thus gives a measure of the percentage of
cells actively undergoing apoptosis. PI on the other hand
gives a measure of cell viability as cells with intact cell
membrane exclude PI. Cells were treated with 100 μM
esculetin for different time points. They were then
stained with allophycocyanin (APC) labeled annexin-V
and PI as per the manufacturer’s guidelines (eBioscience-
s,USA). Population was then analyzed for percentage of
cells in healthy, early apoptotic and late apoptotic phase
on FACScalibur using CellQuestPro software.
Detection of apoptosis by terminal
deoxynucleotidyltransferase dUTP nick end labeling
(TUNEL) assay
DNA fragmentation by endonucleases is one of the pro-
cesses that set in during apoptosis resulting in creation of
multiple 3′hydroxyl ends. These ends are labeled in APO-
BRDU™ assay with bromo-deoxyuridine triphosphates (Br-
dUTP) using terminal deoxynucleotedyl transferase (TdT)
and are identified by flow cytometry by staining the cells
with a FITC-labeled anti-BrdU mAb. Staining was done as
per the manufacturer’s guidelines (BD Pharmingen) and
analyzed on FACScalibur using CellQuestPro software.
Mitochondrial membrane potential assay
Mitochondrial membrane potential was determined in
untreated cells and cells treated with 100 μM esculetin
for different time using MitoProbe JC-1 assay kit (Life
technologies, USA). JC-1, a mitochondrial membrane
potential sensor, is a lipophilic cationic dye that exists as
aggregates in healthy cells and emits red fluorescence.
Whereas, once mitochondrial membrane gets depolar-
ized it exists as monomers in cytoplasm and emit green
fluorescence. Ratio of red and green fluorescence signals
from cells stained with JC-1 dye was recorded and
analyzed on FACScalibur using CellQuestPro software.
Western blot analysis
Cells cultured in T-25 flasks were treated with 100 μM
esculetin for different time intervals. They were lysed in
RIPA buffer (50 mM Tris, 2 mM EDTA, 150 mM NaCl,
1 % Tergitol, 0.5 % sodium deoxycholate, 1 mM PMSF
and 1X Protease Inhibitor) for 45 min at 4 °C and centri-
fugated at 13,000 g for 20 min at 4 °C. Total protein
obtained as supernatant was determined using BCA pro-
tein estimation kit (Bangalore Genei). For collection of
separate nuclear and cytoplasmic extract, NE-PER™
Nuclear and Cytoplasmic Extraction kit (Life Technologies,
USA) was used as per manufacturer’s protocol. Equal
amount of proteins (30–50 μg) were boiled in Laemmli
buffer (2 % SDS, 10 % glycerol, 60 mM Tris-Cl pH 6.8,
bromophenol blue 0.02 %) and separated on (8–12 %)
SDS- polyacrylamide gels (SDS-PAGE) and transferred on
polyvinyldifluoride (PVDF) membrane (Millipore, USA).
Bovine Serum Albumin (BSA), 5 %, was used to block the
PVDF membrane, followed by incubation with desired
primary antibody for 3 h and horseradish peroxidase (HRP)
conjugated secondary antibody for 45 min at 37 °C with
intermittent washing thrice with 0.05 % tween-20 in PBS
(v/v) at room temperature for 15 min each. Immunoreac-
tive bands were probed with the enhanced chemiluminis-
cence (ECL) western blot detection system (Biogene, India)
according to manufacturer’s instructions and viewed in
gel documentation system LAS4000 (FUJIFILM, USA).
Antibodies against caspase 3 (MA191637), caspase 8
(MA141280), caspase 9 (MA112562) and cytochrome C
(MA5-11674) were purchased from Pierce (Thermo
Scientific, USA). Antibody against phosphorylated Nrf2
(ab76026) was purchased from abcam. Antibody against
proliferating cell nuclear antigen (PCNA) (ab18197)
and NF-κB (sc-372) were provided as a kind gift by Prof
Vani Brahmachari and Prof K Natrajan respectively
from Dr. B.R Ambedkar Centre for Biomedical
Research, University of Delhi. Antibody against inhibi-
tor kappa B (IκB) (sc-847) was a kind gift by Prof Alok
C Bharti from Department of Zoology, University of
Delhi. Antibody against β actin (sc-47778), Nrf2 (sc-13032)
and KEAP1 (sc-15246) along with all HRP conjugated
secondary antibodies against rabbit, mouse and goat were
purchased from Santa Cruz (USA).
Measurement of intracellular ROS level
Cells treated with 100 μM esculetin were incubated with
10 μM of 2′,7′-Dichlorofluorescin diacetate (DCFDA) at
37 oC for half an hour. This cell-permeable non-
fluorescent probe gets oxidized to highly fluorescent
2′,7′-dichlorofluorescein upon exposure to ROS. The
cells were then washed with PBS and analyzed on FACS-
calibur using CellQuestPro software.
Co-immunoprecipitation
Untreated and esculetin (100 μM) treated cells were
collected and lysed in buffer (20 mM Tris, 0.5 mM
EDTA, 100 mM NaCl, 0.5 % Tergitol, 1 mM PMSF and
1X Protease Inhibitor). Equal amount of soluble protein
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(0.5 mg) from treated and untreated samples were
allowed to immunoprecipitate overnight with 2 μg of
desired antibody at 4 °C. The immunocomplex was then
allowed to bind to 40 μl of Protein A/G agarose beads
(SantaCruz, USA) and complex was collected by centri-
fugation at 1500 rpm for 5 mins at 4 °C and washed
thrice in lysis buffer. The complex was then eluted by
boiling in SDS-Laemmli buffer with β mercaptoethanol
and fractionated on 10 % SDS-PAGE, followed by west-
ern blot analysis for the desired protein. Equal amount
of input (10 % of total protein used in Co-IP) was used
as endogenous control.
Confocal microscopy
Cells were grown on coverslips placed in 6-well plate and
treated with 100 μM esculetin. Treated cells were fixed
with 2 % PFA (Paraformaldehyde) at room temperature
for 15 mins. Fixed cells were permeablized with perm buf-
fer (0.2 % saponin and 0.1 % BSA), blocked with 5 % BSA
and incubated overnight in anti-Nrf2 antibody at 4 °C and
then in fluorescein (FITC) conjugated secondary antibody
for 2 h at room temperature. After washing the cells, they
were fixed with 4 % PFA and stained with nuclear stain
DAPI (4′,6-diamidino-2-phenylindole). Confocal imaging
was performed with Nikon C2 laser scan confocal micro-
scope with 60× objective magnification, numerical aper-
ture 1.4, refractive index 1.5, Plan Apo optics equipped
with an argon laser, using excitation and emission wave-
length of 490 and 525 nm respectively for FITC and 461
and 500 nm respectively for nuclear stain DAPI (4′,6-dia-
midino-2-phenylindole). Data was analyzed using the NIS
Elements AR software.
RNA purification, cDNA synthesis and qPCR
RNA was isolated from esculetin treated and untreated
cell cultures using RNeasy kit (Qiagen, Netherlands) ac-
cording to manufacturer’s instructions. cDNA was synthe-
sized from 1 μg of RNA using First strand cDNA
synthesis kit (Thermo Scientific, USA) according to the
manufacturer’s protocol. Expression of NAD(P)H:quinone
oxidoreductase 1 (NQO1) gene was measured by carrying
out real-time PCR reactions using gene specific primers
on cDNA so prepared. Reaction mix constituted 1X SYBR
green mix (ROCHE, Switzerland), template cDNA and
0.5 μM primers and PCR was carried out on Applied
Biosystems 7300 RT-PCR system (Life technologies, USA).
Data was collected using SDS 2.2.2 version and relative
expression was calculated using 2-ΔΔCT method with
GAPDH (Glyceraldehyde 3-phosphate dehydrogenase) as
housekeeping control. Following primers were used:
NQO1qFP: 5′ GGCAGAAGAGCACTGATCGTA 3′
NQO1qRP: 5′-TGATGGGATTGAAGTTCATGGC-3′
GAPDH FP: 5′ CAAGGTCATCCATGACAACTTTG 3′
GAPDH RP: 5′ GTCCACCACCCTGTTGCTGTAG 3′
Docking studies
Docking experiments were performed using Discovery
Studio (DS) Client v4.0 package (Accelrys Inc., USA).
The ligand molecule, esculetin, was constructed using
the Build Fragment tool in DS. Hydrogen atoms were
added and valency was monitored followed by the use of
clean geometry application. The ligand was applied with
CHARMm force field, followed by energy minimization
using steepest descent and conjugate gradient methods
till a derivative of 0.001 is achieved. The coordinates for
the X-ray crystal structures of the receptor were ob-
tained from the RCSB protein data bank (PDB ID:
4IQK). For docking studies, initial protein was prepared
by removing all water molecules, heteroatoms, any co-
crystallized solvent and the ligand. Proper bonds, bond
orders, hybridization and charges were assigned using
protein modelling tools followed by application of
CHARMm force field. The ligand was removed and a
site sphere was specified to define the active site of
KEAP1 receptor. Other than KEAP1, modified KEAP1
receptors were also used wherein the amino acids Arg
415 and Arg 483 were replaced by Alanine one by one.
The CDOCKER program of DS 4.0 software was used to
perform docking simulations and score ligand pose
module was performed to determine binding affinity
scores. CDOCKER generates random conformations of
ligands within the active site through high-temperature
molecular dynamics to generate 10 docked ligand poses.
The docking accuracy was evaluated in terms of the root
mean square deviation (RMSD), lying within 2.0 Å
between the docked position and the experimentally
determined position for the ligand. Further, the stability
of enzyme-ligand complex was observed, based on vari-
ous scoring function such as Lig score, PLP, PMF, LUDI
and CDOCKER interaction energy.
Cell based pull-down assay
CNBr-activated Sepharose 4B beads (GE Healthcare)
were coupled with esculetin as described by Lee et al
[24]. Coupled and uncoupled beads were separately
incubated overnight with total cellular protein extract in
reaction buffer [50 mM Tris (pH7.5), 5 mM EDTA,
150 mM NaCl, 1 mM DTT, 0.01 % Tergitol, 0.2 % BSA,
0.2 mM PMSF and 1X protease inhibitor cocktail]. Beads
were washed thrice with reaction buffer followed by
elution of retained protein in laemmli buffer with β mer-
captoethanol. The protein was then fractionated on 10 %
SDS-PAGE and checked for presence of KEAP1 by west-
ern blotting. Further, to assert the specificity of binding,
competition assay was carried out by pre-incubating
total cellular protein with variable concentrations of
esculetin and subsequently using this protein mixture
for pull down assay as described above.
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ADME property prediction
ADME (Absorption, Distribution, Metabolism and
excretion) properties of esculetin were predicted using
ADMET module, v. 4.0 (Accelrys Inc., USA). This gave
an estimate of the physicochemical properties and the
bioavailability of the compounds. Parameters such as
polar surface area (PSA), CYP2D6 (cytochrome P450
2D6 binding), hepatotoxicity, absorption level (Human
intestinal absorption), and PPB (plasma protein binding),
BBB (Predicted brain/blood partition coefficient), and
solubility level (Predicted aqueous solubility) were calcu-
lated. The acceptability of esculetin based on the Lipins-
ki’s rule of five [25] was also estimated from the results.
Statistical analysis
All data is represented as mean ± SD of three independent
experiments. Differences between the means were deter-
mined using one-way analysis of variance (ANOVA). A
value of p < 0.05 was set as the level of significance.
Results
Esculetin induces cytotoxicity and inhibits proliferation of
pancreatic cancer cells
Effect of esculetin on cell viability was determined on
three different pancreatic cancer cell lines- PANC-1,
MIA PaCa-2 and AsPC-1 and on HEK 293 as a control
by MTT assay. It was found to inhibit the growth of all
the three pancreatic cancer cell lines and significantly
reduce the cell number in dose and time dependent
manner with IC50 of 100 μM (Fig. 1A). There was no
cytotoxicity observed in HEK293 cells upon esculetin
treatment (Additional file 1: Figure S1). Further, no
reduction in viability was observed following the treat-
ment of cells with vehicle (DMSO). Henceforth, all the
assays were carried out on pancreatic cancer cells with
100 μM esculetin treatment, with appropriate controls.
To examine the antiproliferative potential of esculetin,
an analysis of distribution of cells into different phases
of cell cycle was done on esculetin treated and untreated
cell culture. DNA histogram analysis, obtained after PI
staining of esculetin treated and untreated pancreatic
cell population, showed a significant increase in the
percentage of cells in G1 phase in all the three cell lines
(Fig. 1B, C). The increase in G1 phase cells was accom-
panied by a reduction in percentage of cells in S and
G2/M phase. Thus treatment with 100 μM esculetin
significantly reduced the growth of population of pan-
creatic cancer cells by arresting the cells in G1 phase.
Esculetin induces apoptosis in pancreatic cancer cells by
activation of caspases
To check whether esculetin treatment is inducing apop-
tosis in cells, annexin-V-APC and PI cytometry assay
was carried out in PANC-1 cells and APO-BrdU TUNEL
Assay was carried out in MIA PaCa-2 and AsPC-1. A
temporal increase in population of cells in early and late
apoptosis could be observed in PANC-1 cells (Fig. 2a, b).
By 36 h of esculetin treatment, more than 50 % of cells
became apoptotic (Fig. 2a, b) and similar results were
obtained in other two cell lines as well (Fig. 2c). It was
then evaluated if apoptotic death was mediated by acti-
vation and cleavage of caspases. Western blot ananlysis
revealed a temporal increase in expression of caspase 3,8
and 9 and their cleaved forms (Fig. 2d).
Loss of mitochondrial membrane potential initiates
apoptosis on esculetin treatment
The role of mitochondria in esculetin induced apoptosis
in pancreatic cancer cells was investigated by examining
change in status of mitochondrial membrane potential
during treatment and determining the levels of cytosolic
cytochrome C. In all the three cell lines, flow cytometric
analysis of esculetin treated and untreated cells, stained
with JC-1, presented a significant decrease in ratio of red
(JC-1 aggregates) to green fluorescence (JC-1 monomers)
on esculetin treatment (Fig. 3a, b; Additional file 2: Figure
S2A,B,C). Further, western blot analysis of cytosolic
protein displayed an increased level of cytochrome C in
esculetin treated cells (Fig. 3c). The results thus confirmed
loss of mitochondrial membrane potential in pancreatic
cancer cells within 12 h of exposure to esculetin.
Esculetin decreases intracellular ROS level and attenuates
NF-κB
To further explore the mechanism of action of esculetin,
intracellular levels of ROS were determined in esculetin
treated and untreated PANC-1 cells using DCFDA
staining followed by flow cytometry. On exposure to es-
culetin, a conspicuous decrease in DCFDA fluorescence
intensity, indicative of ROS levels, was observed in cells
(Fig. 4a, b). The reduction could be seen as early as 4 h
post esculetin treatment and by 16 h of treatment most
of the population shifts to lower ROS level status.
Further, the levels of p65 subunit of NF-κB, a ROS
sensitive transcription factor, and its inhibitor I-κB were
also determined by western blot analysis. The NF-κB
protein levels were found to get decreased significantly
within 8–12 h of esculetin treatment while those of I-κB
remained unaltered (Fig. 4c).
Esculetin activates ARE pathway in PANC-1 cells
Once it became evident that esculetin lowers the level of
ROS in PANC-1 cells, experiments were designed to
unveil the pathway through which this response is
mediated. To examine if esculetin affects the regulation
of ARE pathway, the interaction between the key tran-
scription factor of ARE pathway, Nrf2, and its inhibitor
KEAP1 was inspected in the presence and absence of
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esculetin using Co-IP assay in PANC-1 and MiaPaCa2
cells. A remarkable loss of interaction could be seen by
western blot analysis of immunoprecipitated protein in
both the cell lines (Fig. 5a, b. Additional file 3: Figure
S3). However, there was no change in total endogenous
expression of both the proteins, as evident by western
blotting of input protein. In contrast, an increase in the
amount of phosphorylated form of Nrf2 was observed in
Fig. 1 Effect of esculetin on pancreatic cancer cells: A Effect of different concentrations of esculetin on cell viability using MTT assay in PANC-1,
AsPc-1 and MIA PaCa-2 cell lines. B Cell cycle analysis of different cell lines ((I) PANC-1 (II) AsPc-1 and (III) MIA PaCa-2) in the absence and
presence of esculetin (100 μM) using flow cytometric analysis of DNA content showing cell cycle arrest in G1 phase (a-synchronized population,
b-vehicle control, c- esculetin treated cells for 12 h in I and II and 18 h in III). C Percent distribution of PANC-1 cells in different phases of cell cycle
upon 100 μM esculetin treatment. (V stands for Vehicle control for indicated time, E stands for esculetin treated sample for indicated time). Data
represents the mean ± SD of three independent experiments. The significance was determined using ANOVA (Bonferroni’s test).
Key:*p < 0.05; **p < 0.01; ***p < 0.001; **** p < 0.0001)
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esculetin treated cells, ascertaining the release of Nrf-2
from its inhibitor KEAP1 (Fig. 5c). Further, we observed an
increase in the levels of Nrf2 in nuclear extract of esculetin
treated cells indicating its nuclear accumulation (Fig. 5c).
The localization of Nrf2 was also probed in vivo by confocal
microscopy that asserted its nuclear accumulation on
esculetin treatment (Fig. 5d). An increase (5 fold) in the
expression of NQO1, a direct target of Nrf2, was also
observed by qPCR in esculetin treated cells compared to that
of untreated cells (Fig. 5e). Together these results establish
that esculetin treatment activates ARE pathway pancreatic
cancer cells due to disruption of Nrf2-KEAP1 interaction.
Esculetin binds directly to KEAP1
To explore if there exists a possible interacting mode of
esculetin with KEAP1 (PDB code: 4IQK), molecular
docking studies were performed using the docking pro-
gram, CDOCKER with Discovery Studio 4.0. Esculetin
was docked into the active site of the receptor using the
‘ligand fit’ function (Fig. 6a). The binding affinity
between the esculetin and KEAP1 protein was calculated
using the scoring function module of the Discovery
Studio 4.0. The CDocker energy value for esculetin was
observed to be −19.95 kcal/mol (Table 1). It was found
to interact specifically with the P1 and P3 subpocket of
Fig. 2 Esculetin induces apoptosis in pancreatic cancer cells: a Flow cytometric analysis of PANC-1 cells treated with 100 μM esculetin for
indicated time showed temporal increase in surface expression of apoptotic marker- Annexin V indicating increased population of cells in
apoptotic phase. b Percentage of PANC-1 cells exhibiting fluorescence in all four panels (healthy, early apoptosis, late apoptosis and necrosis)
showing time dependent increase in apoptosis in Ecsuletin treated cells. c Percentage of cells with active APO BrdU indicating apoptosis in the
absence and presence of esculetin (100 μM) as determined using TUNEL assay. d Western blot analysis showing an increase in expression of pro
and active form of caspases (VC stands for vehicle control, E stands for esculetin treated sample for indicated time, CF stands for cleaved form,
numerals represent time of esculetin treatment). Data represents the mean ± SD of three independent experiments. The significance was
determined using ANOVA (Bonferroni’s test). Key:*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001)
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KEAP1 receptor (Fig. 6b). The two aromatic rings of
esculetin were observed to interact via a π-π interaction
with Tyr525 with a bond distance of 4.4 Å and 6 Å
respectively. Further, these rings were also observed to
interact via a π-cationic interaction with Arg415 with a
bond distance of 5.3 Å and 6.6 Å respectively. The
compound was also found to be involved in the forma-
tion of hydrogen bond with the side chain of Arg483
and the main chain of Ala556, with a close distance of
2.1 Å and 2.2 Å, respectively. In addition, the molecule
was stacked in a conformation that allows it to interact
with Ser508, Ser555, Gln530, Gly462 and Ile461
residues via the hydrophobic interaction. Thus, these
simultaneous binding of esculetin with the P1 sub-
pocket of KEAP1 and the strong binding energy sug-
gested the protein to be its direct binding target.
In the next step, Arg 415 and Arg 483 were replaced
by alanine one by one in KEAP1 receptor and ligand
esculetin was docked upon it. Significant changes were
observed in the interaction and binding energy. The
binding energy between esculetin and KEAP1 decreased
to −15.9412 Kcal/mol in case of R415A mutation and to
Fig. 3 Esculetin induces loss of Mitochondrial membrane potential: a Flow cytometric analysis of PANC-1 cells stained with JC-1 dye after 100 μM
esculetin treatment for indicated time showed a temporal decrease in ratio of red fluorescence (JC-1 aggregates) to green florescence (JC-1 monomers).
b Percentage of cells exhibiting monomers and aggregates of JC-1 after treatment of cells with esculetin for different time intervals. c Western blot
analysis showing temporal increase in cytosolic cytochrome C in PANC-1 cells. (VC stands for vehicle control, E stands for esculetin treatment sample
for indicated time, CCCP stands for positive control i.e., carbonyl cyanide 3-chlorophenylhydrazone treated cells, numerals represent time of esculetin
treatment). Data represents the mean ± SD of three independent experiments. The significance was determined using ANOVA (Bonferroni’s test).
Key:*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001)
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Fig. 4 Esculetin lowers ROS levels: a Fluorescence intensity of DCFDA, an indicator of ROS level was determined in PANC-1 cells and it was found
to decrease upon 100 μM esculetin treatment. b Flow cytometric analysis based histogram showing increase in percentage of PANC-1 cells
negative for ROS activity as a function of time of ecsuletin treatment. c Western blot analysis showing temporal decrease in protein levels of ROS
dependent transcription factor NK-κB and uniform levels of its inhibitor I-κB in PANC-1 cells. (VC stands for vehicle control, E stands for esculetin
treated sample for indicated time, and numerals represent time of esculetin treatment). Data represents the mean ± SD of three independent
experiments. The significance was determined using ANOVA (Bonferroni’s test). Key:*p < 0.05; **p < 0.01; ***p < 0.001; **** p < 0.0001)
Fig. 5 Esculetin disrupts Nrf2-KEAP1 interaction: a and b Western Blot analysis of PANC-1 protein extract immuno-precipitated using (a) Nrf2 and
(b) KEAP1 antibody and probed with the other, showing loss of their interaction in esculetin treated cells. Input lane represents western blot
analysis of 10 % of total protein extract used in CoIP indicating endogenous level of probed protein. c Western Blot analysis of total protein and
nuclear extract from esculetin treated PANC-1 cells showing increase in phosphorylated form of Nrf2 and its nuclear accumulation. d Confocal
microscopy view of esculetin treated PANC-1 cells incubated with Nrf2 antibody and probed with FITC (green) labeled secondary antibody
showing an increase in nuclear accumulation of Nrf2. Nuclear staining was done with DAPI (blue). e Change in expression of NQO1, a target of
Nrf2, measured using qPCR, showed about 5 fold increase upon 100 μM esculetin treatment. (C stands for control, VC stands for vehicle control,
Iso stands for isotype Ab control, E stands for esculetin treated sample for indicated time). Data represents the mean ± SD of three independent
experiments. The significance was determined using t test. Key:*p < 0.05; **p < 0.01; ***p < 0.001)
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−16.6062 Kcal/mol in case of R483A mutation in the
binding pocket. Further, most of the interactions previ-
ously observed with wild type KEAP1 were found to be
lost in both mutants (Additional file 4: Figure S4A,B). It
is therefore predicted that these two arginine residues
are pivotal in the binding of esculetin to KEAP1.
To affirm the depicted binding between esculetin and
KEAP1, a pull down assay was performed using esculetin
conjugated Sepharose 4B beads with total cellular pro-
tein extracted from PANC-1 cells. The western blot ana-
lysis of the same clearly shows that the sepharose beads
conjugated with esculetin (5nM and 10nM) could pull
down much more KEAP1 protein than the unconjugated
beads in a concentration dependent manner (Fig. 6c). To
further confirm the specificity of binding, competition
assay was performed using cell extract pre incubated
with 5-20nM of esculetin before pull down. The mixture
was then allowed to bind to affinity column (sepharose
conjugated with esculetin) and the levels of KEAP1 pro-
tein now retained on the affinity column were checked
by western blot analysis. Our results clearly indicated
that pre-incubation of protein with increasing concen-
trations of esculetin resulted in a parallel decrease in
retention of KEAP1 to the affinity column (Fig. 6c). The
pull down assay thus unequivocally proved that esculetin
binds directly to KEAP1.
Pharmacokinetic profile of esculetin
To predict the drug-likeness of esculetin, a few indica-
tors of their pharmacokinetic profiles were predicted
using ADMET module, v. 4.0 (Accelrys Inc., San Diego,
CA). Herein, the aqueous solubility, bloodbrain barrier
penetration, cytochrome P4502D6 binding, hepatotox-
icity, intestinal absorption, and plasma protein binding
were calculated (Table 2). The ADMET hepatotoxicity
probability for esculetin lies within range and thus
doesn’t seem to possess any kind of hepatotoxic effects.
Esculetin was predicted to be non-inhibitor of CYP2D6
enzyme and may be metabolized and excreted success-
fully. It was predicted to bind weakly to plasma proteins,
so it will be available for diffusion or transport across
cell membranes. Further, it showed high aqueous
Fig. 6 Esculetin binds to KEAP1 directly: a 3D Docking model showing esculetin docked to the active site of KEAP1. b 2D interaction diagram of
esculetin with KEAP1. Residues involved in hydrogen-bonding, charge or polar interactions are represented by magenta-colored circles. Residues
involved in van der Waals interactions are represented by green circles. The solvent accessible surface of a residue is represented by a blue halo
around the atom. Hydrogen-bond interactions with amino acid side chain and main chain are represented by a blue and green dashed line,
respectively with an arrow head directed toward the electron donor. π-π and π-cationic interactions are represented by an orange line with
symbols indicating the interaction. c Western blot analysis of competitive pull down assay carried out with esculetin conjugated beads showing a
direct interaction between esculetin and KEAP1. (I stands for input (10 %), B represents protein pulled using non conjugated beads, EB represent
protein pulled using esculetin conjugated sepharose beads)
Table 1 Molecular docking scores of esculetin againt KEAP1
CDOCKER
Energy
CDocker
interaction
energy
Lig
Score
1
Lig
Score
2
-PLP
1
-PLP
2
Jain PMF Ludi
Score
1
−19.9531 −20.5527 2.37 3.63 39.12 35.66 −0.79 59.87 177
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solubility and absorption levels which signifies high
bioavailability of esculetin. The result thus suggests that
esculetin has good physicochemical and pharmacoki-
netic profile.
Discussion
It is estimated that in the coming decade pancreatic car-
cinoma would be amongst the leading cause of death
amongst cancer patients [26]. What makes this fact all
the more alarming is that since 1997 there has been no
improvement in the therapeutic regime for the same,
which continues to be gemcitabine. The low median
overall survival (6.7 months) of the patients, thus make
the identification and development of new therapeutic
compounds cardinal [27]. In our earlier studies we have
demonstrated a plant driven coumarin compound, escu-
letin, to be a potential drug candidate for Acute Myeloid
Leukemia with translocation (8;21) and mutation in
C-Kit gene [13, 14]. In this study, to understand the
mechanism of esculetin action, the antiproliferative and
apoptotic effect was first established in pancreatic cell
lines (PANC-1, MIA PaCa-2 and AsPC-1). We observed
that esculetin treatment could impede the growth of
PANC-1, MIA PaCa-2 and AsPC-1 cells in a dose as
well as time dependent manner with IC 50 determined
to be 100 μM. This IC50 value of esculetin in pancreatic
cells is appreciably lower than its IC50 values deter-
mined in certain other cells- human leukemic cell line
U937 (approximately 200 μM) [7]; human colon cancer
cells HCT116 (approximately 600 μM) [28] and human
hepatocellular carcinoma cells SMMC-7721 (approxi-
mately 2000 μM) [12]. Further, we found esculetin
exposure arrested the cells in G1 phase, which seems to
be its probable mechanism of action. Earlier reports too
reported an increase in population of cells in G1 phase
in various cell lines [14, 28, 29]. However in hepatocellu-
lar carcinoma, esculetin was reported to cause an S
phase arrest. Thus it is definite that the compound
would target pathways differentially depending upon the
cells making it obligatory to investigate the mechanism
followed in different cell types.
Most of the anticancer drugs eventually kill a cancer-
ous cell by induction of apoptosis. Esculetin too has
been reported to activate mitochondrial apoptotic path-
way in cancer cells. In our study we could detect an
increase in active caspases in esculetin treated cells.
There was a marked increase in apoptotic markers on
the surface of esculetin treated cells. In consistence with
previous studies done on apoptosis induction by escule-
tin [12], we too observed loss of mitochondrial
membrane potential in esculetin treated pancreatic
cancer cell lines. The increase in cytosolic levels of cyto-
chrome C explains well the activation and cleavage of
caspase 3 and 9 observed by western blot analysis. How-
ever a similar elevation in cleavage of caspase 8 indicates
activation of extrinsic pathway of apoptosis as well. Thus
our studies on pancreatic cancer cells show that escule-
tin induces apoptosis in these cells through both extrin-
sic and intrinsic pathways.
A characteristic feature of cancer cells is an elevated
ROS level which is attributed to excessive metabolic
activity and damaged mitochondrial function. Further,
ROS is required for cell cycle progression, inflammation,
tumor growth and metastasis [21]. This rationalizes the
recent development in ROS abrogating strategies to kill
cancer cells. In our study, esculetin, an antioxidant, was
speculated to mediate its effect in cancer cells through
ROS modulation. As anticipated, we could perceive a
decrease in ROS levels in PANC-1 cells on esculetin
treatment. Various antioxidant agents have been shown
to suppress tumor cell growth and in pancreatic cancer
cells particularly, ROS production has already been
shown to promote cell survival [30]. In understanding
thoroughly the potential pathway pursued by esculetin,
we checked the change in the levels of ROS sensitive
transcription factor NF-κB in esculetin treated cells and
we could detect an explicit decline in the same.
Enhanced activity of NF-κB has already been reported to
be associated with increased cell survival and prolifera-
tion due to elevated expression of antiapoptotic protein
Bcl-2 and Bcl-xl as well as c-Myc and cyclin D1 that
promotes progression of cell cycle from G1 to S phase
[31, 32]. Further, certain other antioxidant agents like
curcumin and other polyphenols and N-acetyl-L-cyst-
eine (NAC) have been also found to impede cell cycle
progression and promote apoptosis by inhibiting NF-κB
Table 2 Predicted ADMET properties of the esculetin
Lipinski rule
of five violations
PSA BBB level Absorption level PPB level Solubility level CYP2D6 Hepatoxicity level
0 67.861 3 0 2 4 0 0
BBB stands for blood brain barrier, PSA stands for Polar surface area, PBP stands for plasma protein binding, CYP2D6 stands for Cytochrome P450 2D6
PSA (60–70 Å2)
BBB level (0 very high, 1 high, 2 medium, and 3 very low)
Absorption level (0 good, 1 moderate, 2 low, and 3 very low)
PPB (0 very high, 1 high, 2 medium, and 3 very low)
Solubility level (4 very high, 3 high, 2 medium, and 1 very low)
CYP2D6 (0 non-inhibitor and 1 inhibitor)
Hepatoxicity level (0 is non toxic, 1 is toxic)
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activity [32–36]. Based on our results, and the support-
ing literature, we could remark that esculetin too pro-
duce anticancer response in PANC-1 cells by scavenging
ROS and attenuating NF-κB activity. We also observed
that the levels of its inhibitor (I-κB) remain the same
upon esculetin treatment.
In an endeavor to identify the direct target of esculetin
important leads from the results hitherto suggested scru-
tinizing the pathway responsible for declined ROS levels
in esculetin treated PANC-1 cells. Further, inhibition of
NF-κB by several antioxidants correlates with their redox
capabilities and strong interplay between NF-κB and Nrf2
have been reported [36–40]. We thus explored the effect
of esculetin treatment on the regulation of Nrf2, the mas-
ter regulator of antioxidant activity. Nrf2, which combats
the oxidative stress in a cell as an important anti-
neoplastic factor and is emerging as a key target of cancer
chemoprevention and chemotherapy [41]. Much the same
as role of ROS, the role of Nrf2 is also debatable in cancer.
Cancer cells have a tendency to hijack the regulatory
machinery of Nrf2, whereby they maintain their intracellu-
lar ROS level within the range required for their proper
growth and survival [42]. Basal expression levels of Nrf2
have been reported to be low in PANC-1 while that of it’s
inhibitor KEAP1are reported to be high [43]. Although
strategies inhibiting Nrf2 have gained focus as anticancer
therapy [44, 45], yet its tumor suppressor role cannot be
negated and there are still a number of studies focusing
on developing small molecules that could inhibit Nrf2-
KEAP1 interaction [17, 46–51]. Naurally occurring
compounds like curcumin, lycopene, sulforaphane, ogano-
sulfur compounds in garlic etc have been reported as
potent activators of Nrf2 by inhibiting KEAP1, which has
been linked to their chemopreventive and chemothera-
peutic effects [51–53]. Further, synthetic compounds
including triterpenoids derivatives like Bardoxolone
methyl [RTA 408, methyl ester of cyano-3,12-dioxooleana-
1,9(11)- dien-28-oic (CDDO- Me] too are being developed
as anticancer agents along the same line [23, 54]. Such in-
hibitors would ultimately tend to decrease the intracellular
ROS levels below the threshold required for cancer cells to
proliferate. We too hereby provide evidence that there is a
decreased interaction of Nrf2 with its inhibitor KEAP1 in
esculetin treated cells whereas their endogenous levels
remain unaltered. Upon release, Nrf2 is phosphorylated
and transported to the nucleus wherein it binds to
promoter with ARE sequence and activates the target genes
encoding proteins that scavenge ROS and poses
antagonistic effect on NF-κB pathway. Thus we propose
that in pancreatic cancer cells there is a loss of interaction
between Nrf2 and KEAP1 on exposure to esculetin that ul-
timately depletes ROS and abrogate NF-κB activity.
Shepherded by the already established leads, we exco-
gitated to check if esculetin could bind directly to
KEAP1. To ascertain the same, both in silico and in vitro
approaches were followed. The binding cavity of KEAP 1
is divided into 5 subpockets as P1, P2, P3, P4 and P5,
where two subpocket, P1 and P2, play significant role in
strong binding interactions and contribute to total bind-
ing free energy. The P1, formed by residues Ser508,
Phe478, Ile461, Arg483, Arg415, and Gly462, is highly
positively charged and the electrostatic interactions with
the Arg483 and Arg415 are significant for binding. The
P2 subpocket, consisting of Ser363, Arg380, Asn382,
and Asn414, is also positively charged whereas Arg415,
located at the border of the P1 and P2, may take part in
the P1 and P2 simultaneously. The peptide backbone oc-
cupies the P3 subpocket which is composed of Gly509
Ala556, Ser555, Ser602, Gly603, and Gly571 [22]. Mo-
lecular docking studies predicted significant hydrogen
bond, π–cationic and π–π aromatic interactions between
esculetin and residues in the subpocket P1 and P3 of the
KEAP1 receptor, with a CDocker energy value of
−19.95 kcal/mol. It was worth noticing that KEAP1 resi-
dues Arg 415 and Arg 483 were found to be involved in
interaction with esculetin in our study, which have been
reported in structural studies to be involved in Nrf2-
KEAP1 binding by forming hydrogen bonds with Glu 78
of Nrf2 [55]. Mutagenesis experiments have provided
strong evidences that individual substitution of these
two amino acids in KEAP1 impaired its ability to bind
with Nrf2 and to mediate repression of Nrf2-dependent
gene expression [56, 57]. Herein, we also observed that
alanine substitution of these residues in molecular
docking experiments reduced the binding potential be-
tween esculetin and KEAP1 indicating their importance in
KEAP1-esculetin interaction. Thus it is evident that both
the interactions, Nrf2-KEAP1 and KEAP1-esculetin,
involve same residues and apparently esculetin com-
petes with Nrf2 for binding with KEAP1. Binding be-
tween esculetin and KEAP1 was further confirmed in
vitro with pull down assay using esculetin conjugated
beads. The variation in the amount of KEAP1 pulled
down, an increase with increase in amount of escule-
tin coupled with beads and a decrease with increase
in concentration of competing free esculetin, makes it
evident enough that esculetin binds directly to
KEAP1. The existence of this direct binding of escule-
tin to KEAP1, involving the same residues of KEAP1
as involved in its interaction with Nrf2, along with
observed loss of Nrf2-KEAP1 interaction in pancreatic
cancer cells upon esculetin treatment stipulates that
esculetin perturbs the binding between Nrf2 and
KEAP1.
An important requisite for a promising candidate to be
developed as a drug is an investigation of its pharmaco-
logical properties. ADMET studies are expected to reduce
the risk of late-stage attrition of drug development. Given
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the fact that esculetin has antiproliferative effects on
cancer cells, it justifies itself to be screened for its drug
likeness and our results strongly support esculetin to be a
potential drug candidate.
Conclusion
To conclude we can assert that esculetin is a good
potential therapeutic agent for pancreatic cancer, where
it activates the Nrf2-ARE pathway by binding to KEAP1
protein and ultimately suppresses cancer cell population
growth through ROS sensitive transcription factor NFκB.
Further studies should be carried out using animal
models to check its efficacy and toxicity.
Additional files
Additional file 1: Figure S1. Effect of esculetin on HEK293 cancer cells:
Effect of different concentrations of esculetin on cell viability using MTT
assay in HEK 293 cell line. Data represents the mean ± SD of three
independent experiments. (TIF 23 kb)
Additional file 2: Figure S2. Esculetin induces loss of Mitochondrial
membrane potential: A- Flow cytometric analysis of MiaPaCa-2 cells
stained with JC-1 dye after 100 μM esculetin treatment for indicated time
showed a temporal decrease in ratio of red fluorescence
(JC-1 aggregates) to green florescence (JC-1 monomers). B,C- Percentage
of MiaPaCa-2 cells (B) and AsPC-1 (C) exhibiting monomers and
aggregatesof JC-1 after treatment of cells with esculetin for different time
intervals. (VC stands for vehicle control, E stands for esculetin treatment
sample for indicated time, CCCP stands for positive control i.e., carbonyl
cyanide 3-chlorophenylhydrazone treated cells, numerals represent time
of esculetin treatment). Data represents the mean ± SD of two independent
experiments. The significance was determined using ANOVA (Bonferroni’s
test). Key:*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001). (TIF 294 kb)
Additional file 3: Figure S3. Esculetin disrupts Nrf2-KEAP1 interaction:
Western Blot analysis of MiaPaCa-2 protein extract immuno-precipitated
using Nrf2 antibody and probed with KEAP-1, showing loss of their
interaction in esculetin treated cells. Input lane represents western blot
analysis of 10 % of total protein extract used in CoIP indicating
endogenous level of probed protein. (C stands for control, VC stands for
vehicle control, Iso stands for isotype Ab control, E stands for esculetin
treated sample for indicated time). (TIF 208 kb)
Additional file 4: Figure S4. Interaction between esculetin and mutant
KEAP1: 2D interaction diagram of esculetin with (A) KEAP1 R415A and (B)
KEAP1 R483A. Residues involved in hydrogen-bonding, charge or polar
interactions are represented by magenta-colored circles. Residues involved
in van der Waals interactions are represented by green circles. The solvent
accessible surface of a residue is represented by a blue halo around the
atom. Hydrogen-bond interactions with amino acid side chain and main
chain are represented by a blue and green dashed line, respectively with an
arrow head directed toward the electron donor. (TIF 164 kb)
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